David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member of the Rocky Mountain Cancer’s Research Executive Committee, is scheduled to participate in an upcoming interview. During this discussion, he will provide insights into his recent study, titled “Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL / SLL in the US Community Setting.”
In the interview, Dr. Andorsky will offer an overview of the study, highlighting changes in the treatment landscape of BTK inhibitors for CLL / SLL. Specifically, he will discuss variations in the use of ibrutinib, acalabrutinib, and zanubrutinib over the observation period, exploring factors influencing these shifts and their implications for patient outcomes.
Additionally, Dr. Andorsky will delve into the analysis of social determinants of health (SDOH) within the study, including rural/urban status, socioeconomic status (SES), and Medicaid coverage among patients receiving BTK inhibitors. He will elaborate on observed differences in rural/urban status across treatment regimens, discussing the potential impact of these differences on treatment choices and outcomes.
Moreover, the interview will address the study’s findings indicating similarities in SES and Medicaid coverage across treatment sequences, challenging existing assumptions about their influence on prescribing patterns. Dr. Andorsky will share insights on how these findings might reshape our understanding of the role of SES and insurance coverage in treatment decisions for CLL / SLL patients receiving BTK inhibitors, and he will outline potential areas for additional research and considerations in this context.